代表性成果 （論文/專利/專著等） |
SCI論文： 1.Guo C, Zhang Y, Xue H, Zhao X, Wang B, Deng L, Zhu X, Zhang X, Zhang Y, Liu Y. Butein Alleviates Non-Alcoholic Steatohepatitis in Leptin-Deficient Mice by Modulating the PDE4/cAMP/p-CREB Pathway. Drug Des Devel Ther. 2025 Aug 14;19:7015-7031. doi: 10.2147/DDDT.S530855. PMID: 40831700; PMCID: PMC12360368. 2.Li Z, Wei H, Li R, Wu B, Xu M, Yang X, Zhang Y*, Liu Y*. The effects of antihypertensive drugs on glucose metabolism. Diabetes Obes Metab. 2024 Aug 14. doi: 10.1111/dom.15821. Epub ahead of print. PMID: 39140233. 3.Wu B, Li R, Hao J, Qi Y, Liu B, Wei H, Li Z, Zhang Y*, Liu Y*. CT semi-quantitative score used as risk factor for hyponatremia in patients with COVID-19: a cross-sectional study. Front Endocrinol (Lausanne). 2024 Jun 14;15:1342204. doi: 10.3389/fendo.2024.1342204. PMID: 38948513; PMCID: PMC11211362. 4.Li M, Yang X, Li R, Wu B, Hao J, Qi Y, Bai T, Yang L, Zhang Y*, Liu Y*. Visceral Fat Area and Subcutaneous Fat Area Increase in Hyperthyroidism Patients After Treatment-A Single-Group Repeated-Measures Trial. Diabetes Metab Syndr Obes. 2024 May 27;17:2165-2176. doi: 10.2147/DMSO.S458486. PMID: 38827164; PMCID: PMC11141577. 5.Han M, Cao X, Zhang J, Yang X, Zhang Y*, Liu Y*. Association of Aldosterone, Renin, and Aldosterone to Renin Ratio with Metabolic Profile in Primary Aldosteronism. Diabetes Metab Syndr Obes. 2024 May 18;17:2065-2074. doi: 10.2147/DMSO.S457243. PMID: 38778907; PMCID: PMC11110821. 6.Li R, Wu B, Han M, Li M, Yang X, Zhang J, Zhang Y*, Liu Y*. Uric Acid Metabolic Disorders in Pituitary-Target Gland Axis. Diabetes Metab Syndr Obes. 2024 Feb 7;17:661-673. doi: 10.2147/DMSO.S448547. PMID: 38343584; PMCID: PMC10859102. 7.Xu M, Hao J, Qi Y, Wu B, Li R, Yang X, Zhang Y*, Liu Y*. Causal effects of gut microbiota on diabetic neuropathy: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2024 Aug 2;15:1388927. doi: 10.3389/fendo.2024.1388927. PMID: 39157679; PMCID: PMC11329939. 8.Wang R, Chen K, Liu S, Ren R, Hou H, Zeng Q, Zhang Y*, Liu Y*. Design, synthesis and biological evaluation of novel oxazole derivatives as potential hypoglycemic agents. Bioorg Med Chem. 2024 Nov 15;114:117961. doi: 10.1016/j.bmc.2024.117961. Epub 2024 Oct 18. PMID: 39437535. 9.Ruifeng Wang, Xin Zhao, Hongbao Hou, Ke Chen, Shuihua Liu, Ruyue Ren, Yunfeng Liu*, Yi Zhang*. Cutting-Edge FAK-targeting PROTACs: design, synthesis, and biological Evaluation. Journal of Chinese Pharmaceutical Sciences. 2024, Vol. 33:Issue (9): 767-782.DOI: 10.5246/jcps.2024.09.057 10. Jiao JJ, Hu Y, Cui YJ, Tuo CM, Wang YX, Li XY, Zhang Y, Wu MN. Anisomycin alleviates cognitive impairments and pathological features in 3xTg-AD mice. Neuropharmacology. 2024 Sep 18:110159. doi: 10.1016/j.neuropharm.2024.110159. Epub ahead of print. PMID: 39303856. 11. Zhang X, Shi X, Zhang X, Zhang Y, Yu S, Zhang Y, Liu Y. Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database. Biomed Pharmacother. 2024 Sep;178:117293. doi: 10.1016/j.biopha.2024.117293. Epub 2024 Aug 13. PMID: 39142251. 12. Zhao X, Zeng Q, Yu S, Zhu X, Bin Hu, Deng L, Zhang Y, Liu Y. GLP-1R mediates idebenone-reduced blood glucose in mice. Biomed Pharmacother. 2024 Sep;178:117202. doi: 10.1016/j.biopha.2024.117202. Epub 2024 Jul 24. PMID: 39053424. 13. Wang B, Zhu X, Yu S, Xue H, Deng L, Zhang Y, Zhang Y, Liu Y. Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice. Biochem Biophys Res Commun. 2024 Aug 30;722:150170. doi: 10.1016/j.bbrc.2024.150170. Epub 2024 May 23. PMID: 38797152. 14. Li M, Zhang J, Yang G, Zhang J, Han M, Zhang Y, Liu Y. Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2023 Jun;79(6):859-871. doi: 10.1007/s00228-023-03490-8. Epub 2023 Apr 25. PMID: 37097298. 15. Zhang J, Li MN, Yang GM, Hou XT, Yang D, Han MM, Zhang Y, Liu YF. Effects of water-sodium balance and regulation of electrolytes associated with antidiabetic drugs. Eur Rev Med Pharmacol Sci. 2023 Jun;27(12):5784-5794. doi: 10.26355/eurrev_202306_32817. PMID: 37401315. 16. Li M, Liu Z, Yang X, Zhang J, Han M, Zhang Y, Liu Y. The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: A systematic review and meta-analysis. J Diabetes Complications. 2023 Dec;37(12):108632. doi: 10.1016/j.jdiacomp.2023.108632. Epub 2023 Oct 21. PMID: 37907042. 17. Xue H, Xing HJ, Wang B, Fu C, Zhang YS, Qiao X, Guo C, Zhang XL, Hu B, Zhao X, Deng LJ, Zhu XC, Zhang Y, Liu YF. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis. Drug Des Devel Ther. 2023 May 11;17:1417-1432. doi: 10.2147/DDDT.S404055. PMID: 37197367; PMCID: PMC10184894. 18. Li M, Zhang J, Yang G, Zhang J, Han M, Zhang Y, Liu Y. Effects of Anterior Pituitary Adenomas' Hormones on Glucose Metabolism and Its Clinical Implications. Diabetes Metab Syndr Obes. 2023 Feb 13;16:409-424. doi: 10.2147/DMSO.S397445. PMID: 36816815; PMCID: PMC9937076. 19. Zhao X, Deng L, Ren L, Yang H, Wang B, Zhu X, Zhang X, Guo C, Zhang Y, Liu Y. VPAC2 receptor mediates VIP-potentiated insulin secretion via ion channels in rat pancreatic β cells. Exp Cell Res. 2023 Feb 15;423(2):113471. doi: 10.1016/j.yexcr.2023.113471. Epub 2023 Jan 13. PMID: 36642263. 20. Dan Yang, Xintong Hou, Guimei Yang, Mengnan Li, Jian Zhang, Minmin Han, Yi Zhang, Yunfeng Liu. Effects of the POMC System on Glucose Homeostasis and Potential Therapeutic Targets for Obesity and Diabetes. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy. 2022 Sep 25;15:2939-2950.doi: 10.2147/DMSO.S380577 21. Xintong Hou, Dan Yang, Guimei Yang, Mengnan Li, Jian Zhang, Jiaxin Zhang, Yi Zhang, Yunfeng Liu. Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes.Frontiers in Endocrinology. 2022 Sep 20;13:984198.doi: 10.3389/fendo.2022.984198. 22. Zhao X, Cui L, Zhang Y, Guo C, Deng L, Wen Z, Lu Z, Shi X, Xing H, Liu Y, Zhang Y. Screening for Potential Therapeutic Agents for Non-Small Cell Lung Cancer by Targeting Ferroptosis.Front Mol Biosci. 2022 Jul 14;9:917602. doi: 10.3389/fmolb.2022.917602. eCollection 2022.（2區(qū)） 23. Tao Liu , Lijuan Cui, Huan Xue, Xiaohua Yang, Mengmeng Liu, Linping Zhi, Huanhuan Yang, Zhihong Liu, Min Zhang, Qing Guo, Peifeng He, Yunfeng Liu, Yi Zhang. Telmisartan Potentiates Insulin Secretion via Ion Channels, Independent of the AT1 Receptor and PPARγ. Front Pharmacol . 2021 Sep 14;12:739637. doi: 10.3389/fphar.2021.739637. eCollection 2021.（2區(qū)） 24. Xin Zhao, Minghe Wang, Lijuan Cui, Chao Fu, Zhihong Lu, Zhitong Wen, Huan Xue, Yunfeng Liu* and Yi Zhang*. GLP-1 Receptor Agonists: Beyond Its Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug 23;12:721135. doi: 10.3389/fendo.2021.721135. eCollection 2021（2區(qū)） 25. Zhihong Liu，Huanhuan Yang，Linping Zhi，Huan Xue，Zhihong Lu，Yanli Zhao，Lijuan Cui，Tao Liu，Shouan Ren，Peifeng He，Yunfeng Liu and Yi Zhang*. Sphingosine 1-phosphate stimulates insulin secretion and improves cell survival by blocking voltage-dependent K + channels in β cells.Frontiers in Pharmacology, 2021. 12：683674. doi: 10.3389/fphar.2021.683674（2區(qū)） 26. Xiaohua Yang, Min Zhang, Zhihong Lu, Linping Zhi, Huan Xue, Tao Liu, Mengmeng Liu, Lijuan Cui, Zhihong Liu, Peifeng He, Yunfeng Liu* and Yi Zhang*. Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist S6 Stimulates Insulin Secretion From Rat Islets. Frontiers in Pharmacology, 2021 Apr 29; 12:664802. doi: 10.3389/fphar.2021.664802. eCollection 2021.（2區(qū)） 27. Lijuan Cui, Huan Xue, Zhitong Wen, Zhihong Lu, Yunfeng Liu, Yi Zhang*. Prognostic roles of metabolic reprogramming-associated genes in patients with hepatocellular carcinoma. Aging, 2020 Nov 12;12(21):22199-22219. doi: 10.18632/aging.104122. Epub 2020 Nov 12.（1區(qū)） 28. T. BAI, H. YANG, H. WANG, L. ZHI, T. LIU, L. CUI, W. Liu, Y. Wang, M. ZHANG, Y. Liu and Y. ZHANG*, Inhibition of voltage-gated K+ channels mediates docosahexaenoic acid-stimulated insulin secretion in rat pancreatic β-cells.[J] . Food & Function, 2020, DOI:10.1039/D0FO01891K.（1區(qū)） 29. Minmin Han, Xiaoming Cao, Changjian Zhao, Luyang Yang, Nan Yin, Pengliang Shen, Jin Zhang, Fei Gao, Yi Ren, Dong Liang, Jing Yang, Yi Zhang* and Yunfeng Liu*. Assessment of Glycometabolism Impairment and Glucose Variability Using Flash Glucose Monitoring System in Patients With Adrenal Diseases. Front Endocrinol (Lausanne). 2020 September;11 doi: 10.3389/fendo.2020.544752（2區(qū)） 30. Cui LJ, Bai T, Zhi LP, Liu ZH, Liu T, Xue H, Yang HH, Yang XH, Zhang M, Niu YR, Liu YF, Zhang Y*. Analysis of long noncoding RNA-associated competing endogenous RNA network in glucagon-like peptide-1 receptor agonist-mediated protection in β cells. World J Diabetes 2020; 11(9): 374-390 31. Mengmeng Liu, Lele Ren, Xiangqin Zhong, Yaqin Ding, Tao Liu, Zhihong Liu, Xiaohua Yang, Lijuan Cui, Lijun Yang, Yanying Fan, Yunfeng Liu, Yi Zhang* . D2-Like Receptors Mediate Dopamine-Inhibited Insulin Secretion via Ion Channels in Rat Pancreatic β-Cells. Front Endocrinol (Lausanne). 2020 Apr 7;11:152. (通訊作者)2區(qū)，3.644 32. Liu M, Yang X, Bai T, Liu Z, Liu T, Wang Y, Cui L, Liu Y, Zhang Y*. PACAP stimulates insulin secretion by PAC1 receptor and ion channels in β-cells. Cell Signal. 2019 Sep;61:48-56. (通訊作者)2區(qū)，3.388 33. Liu Y, Zhong X, Ding Y, Ren L, Bai T, Liu M, Liu Z, Guo Y, Guo Q, Zhang Y, Yang J, Zhang Y*. Inhibition of voltage-dependent potassium channels mediates cAMP-potentiated insulin secretion in rat pancreatic β cells. Islets. 2017 Mar 4;9(2):11-18. (通訊作者). 4區(qū)，1.879 34. Gao J, Bai T, Ren L, Ding Y, Zhong X, Wang H, Guo Y, Li J, Liu Y, Zhang Y*, The PLC/PKC/Ras/MEK/Kv channel pathway is involved in uncarboxylated osteocalcin-regulated insulin secretion in rats. Peptides. 2016 Dec;86:72-79. (通訊作者) 3區(qū)，2.659 35. Zhang Y*, Ding Y, Zhong X, Guo Q, Wang H, Gao J, Bai T, Ren L, Guo Y, Jiao X, Liu Y. Geniposide acutely stimulates insulin secretion in pancreatic β-cells by regulating GLP-1 receptor/cAMP signaling and ion channels. Mol Cell Endocrinol. 2016 Jul 15;430:89-96. (通訊作者)2區(qū)，3.693 36. Gao J, Zhong X, Ding Y, Bai T, Wang H, Wu H, Liu Y, Yang J, Zhang Y*. Inhibition of voltage-gated potassium channels mediates uncarboxylated osteocalcin-regulated insulin secretion in rat pancreatic β cells. Eur J Pharmacol. 2016 Apr 15;777:41-8.(通訊作者)3區(qū)，3.17 37. Zhang Y*, Wang H, Guo Q, Li X, Gao J, Liu Y, Yang C, Niu L, Yang J. PI3K is involved in P2Y receptor-regulated cAMP /Epac/Kv channel signaling pathway in pancreatic β cells. Biochem Biophys Res Commun. 2015 Oct 2;465(4):714-8. (通訊作者)3區(qū)，2.705 38. Zhang Y*, Guo Q, Li X, Gao J, Liu Y, Yang J, Li Q. P2Y purinergic receptor-regulated insulin secretion is mediated by a cAMP/Epac/Kv channelpathway. Biochem Biophys Res Commun. 2015 May 8;460(3):850-6. （通訊作者)3區(qū)，2.705 39. Li X, Guo Q, Gao J, Yang J, Zhang W, Liang Y, Wu D, Liu Y*, Weng J, Li Q, Zhang Y*. The adenylyl cyclase inhibitor MDL-12,330A potentiates insulin secretion via blockade of voltage-dependent K+ channels in pancreatic beta cells. PLOS one. 8(10):e77934.2013 （通訊作者）3區(qū)，2.776 40. Liu Y*, Zhang Y*, Zhu D*, Gaisano HY. VAMP8 Deletion Delays the Onset of Streptozotocin-Induced Hyperglycemia. Can J Diabetes. 36 (2012) 251e256（*共同第一作者）4區(qū)，2.887 41. Zhu D*, Zhang Y*, Lam PP*, Dolai S*, Liu Y*, Cai EP, Choi D, Schroer SA, Kang Y, Allister EM, Qin T, Wheeler MB, Wang CC, Hong WJ, Woo M, Gaisano HY.Dual Role of VAMP8 in Regulating Insulin Exocytosis and Islet β Cell Growth. Cell Metab. 2012 Aug 8;16(2):238-49. （*共同第一作者）top 1區(qū)，22.415 42. Kang Y*, Zhang Y*, Liang T*, Leung YM, Ng B, Xie H, Chang N, Chan J, Shyng SL, Tsushima R, Gaisano HY. ATP modulates interaction of syntaxin-1A with sulfonylurea receptor 1 to regulate pancreatic beta-cell KATP channels. J Biol Chem. 2011 Feb 18;286(7):5876-83.（*共同第一作者） 2區(qū)，4.106 43. Zhang Y, Kang Y, Lam PPL, Chang N, Liu Y, Olkkonen VM, Gaisano HY. Cab45b, a Munc18b Interacting-Partner, Regulates Exocytosis in Pancreatic Beta Cells. J Biol Chem. 2009 Jul 31;284(31):20840-7，（第一作者）2區(qū)，4.106 44. Zhang Y*, Liu Y*, Qu J, Zhang N, Diao J, Strijbos P, Tsushima R, Robinson RB, Gaisano HY, Wang Q, Wheeler MB. Functional Characterization of HCN Channels in Rat Pancreatic β Cells. Journal of Endocrinology 2009 Oct;203(1):45-53， (通訊作者) 2區(qū)，4.381 45. Zhang Y, Zhang N, Gyulkhandanyan AV, Xu E, Gaisano HY, Wheeler MB, Wang Q. Presence of functional hyperpolarisation-activated cyclic nucleotide-gated channels in clonal alpha cell lines and rat islet alpha cells. Diabetologia. 2008 Dec;51(12):2290-8.（第一作者）2區(qū)，7.113 46. Xu E*, Kumar M*, Zhang Y, Ju W, Obata T, Zhang N, Liu S, Wendt A, Deng S, Ebian Y, Wheeler MB, Braun M, Wang Q. Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. Cell Metabolism 2006; 3(1):47-58 （第二作者） top 1區(qū)，22.415 發(fā)明專利： 1. 日本專利：アニンマイシソ誘導(dǎo)體、アニンマイシソ及びその誘導(dǎo)體をG L P-1R作動(dòng)薬としての使用方法，特許第７５６６３７８號(hào)；授權(quán)日期：2024.10.04 2. 一種GLP-1R激動(dòng)劑。專利號(hào)：ZL 2023 1 0498208.X；授權(quán)日期：2025.02.11 3. 一種式(I)化合物制備鎮(zhèn)痛藥物中的用途。專利號(hào)：ZL 2022 1 0884726.0； 授權(quán)日期：2023.11.17 4. 一種化合物在制備治療阿爾茲海默癥藥物中的用途。專利號(hào)：ZL 2022 1 0884725.6；授權(quán)公告日：2024. 02. 02 5. 一種用于非酒精性脂肪肝病的化合物、組合物及其用途。專 利 號(hào)：ZL 2022 1 0878875.6 授權(quán)日期：2023年08月25日 6. 一種茴香霉素衍生物以及茴香霉素和其衍生物作為GLP-1R激動(dòng)劑的用途。專利號(hào)：ZL 2021 1 0103556.3；授權(quán)日期：2023年05月30日 7. 一種小分子GLP-1R激動(dòng)劑及其應(yīng)用。專利號(hào)：ZL 2020 1 0498224.5。授權(quán)日期：2021.4.23 8. 國(guó)家發(fā)明專利：一種小分子GLP-1R激動(dòng)劑及其應(yīng)用。授權(quán)號(hào)：ZL 2020 1 0498224.5。授權(quán)日期：2021.4.23 （第一發(fā)明人） 9. 一種治療乳腺癌的藥物組合物。專 利 號(hào)：ZL 2023 1 0041357.3； 授權(quán)日期：2025年03月14日 10. 一種便于控制注射量的胰島素注射筆。授權(quán)號(hào)：ZL 2020 2 2755790.8；授權(quán)日期：2021.12.28 |
